Established in 2020 Wednesday, March 27, 2024


Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose
A health worker prepares to inoculate a pregnant woman with the Pfizer-BioNTech vaccine against COVID-19 at a vaccination center in Bogota, on July 23, 2021. Raul Arboleda / AFP.



BOSTON, MASS.- In a multi-hospital analysis of individuals who experienced an allergic reaction to their first mRNA COVID-19 vaccine dose, all patients who went on to receive a second dose tolerated it without complications. The research, which was led by allergists at Massachusetts General Hospital and is published in JAMA Internal Medicine, indicates that a first dose reaction to COVID-19 vaccination should not keep people from getting a second dose.

Allergic reactions after mRNA COVID-19 vaccinations have been reported to be as high as 2%, with anaphylaxis—a life-threatening whole-body allergic reaction—occurring in up to 2.5 per 10,000 people. To examine whether it’s safe to proceed with a second mRNA COVID-19 vaccine dose after a dose one reaction, investigators from MGH, Vanderbilt University Medical Center, University of Texas Southwestern Medical Center and Yale School of Medicine combined data from patients who sought allergy specialist care at their hospitals after a reaction to their first mRNA COVID-19 vaccine dose. “These reactions could include symptoms such as itching or hives or flushing. The patients included were all advised by allergy specialists after their dose one reaction,” explains co–lead author Matthew S. Krantz, MD, of Vanderbilt University Medical Center.




Among 189 patients, 32 (17%) experienced anaphylaxis after their first dose of mRNA COVID-19 vaccine. A total of 159 patients (84%) went on to receive a second dose. All 159 patients, including 19 individuals who had experienced anaphylaxis following the first dose, tolerated the second dose. Thirty-two patients (20%) reported immediate and potentially allergic symptoms associated with the second dose that were self-limited, mild, and/or resolved with antihistamines alone.

“One important point from this study is that these immediate onset mRNA vaccine reactions may not be mechanistically caused by classic allergy, called immediate hypersensitivity or Ig-E–mediated hypersensitivity. For classic allergy, re-exposure to the allergen causes the same or even worse symptoms,” says co–senior author Kimberly G. Blumenthal, MD, MSc, co-director of the Clinical Epidemiology Program within MGH’s Division of Rheumatology, Allergy and Immunology.

The study’s findings suggest that it’s safe for most individuals to receive a second dose of the mRNA COVID-19 vaccine, notes co–senior author Aleena Banerji, MD, clinical director of the Allergy and Clinical Immunology Unit at MGH. “After first dose reactions, allergy specialists may be useful to help guide risk/benefit assessments and assist with completion of safe vaccination,” she says.

This study was funded by the National Institutes of Health and MGH.







Today's News

July 28, 2021

Decoding the secrets of a 310 million-year-old brain

Brain fingerprints help doctors detect neurological disease

Astronomers show how planets form in binary systems without getting crushed

Under pressure, 'squishy' compound reacts in remarkable ways

Highly potent, stable nanobodies stop Sars-CoV-2

Synthetic tissue model with blood vessels

Random effects make it difficult to optimise antibiotic therapy

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose

Novel discovery describes the mechanisms of wound detection in the body

More than just walking: a new role for core brain region

Vaccination against hereditary colorectal cancer successful in mice

How cells draw on memories of past inflammation to respond to new threats

Chronic pain might impact how the brain processes emotions

Another byproduct of the pandemic: paranoia

Genetic variant linked to hearing loss in children treated with common chemotherapy drug

Engineers may learn from bees for optimal honeycomb designs

Scientists identify five new plant species in Bolivia

New tests can detect tiny but toxic particles of coal ash in soil



 


Editor & Publisher: Jose Villarreal
Art Director: Juan José Sepúlveda Ramírez



Tell a Friend
Dear User, please complete the form below in order to recommend the ResearchNews newsletter to someone you know.
Please complete all fields marked *.
Sending Mail
Sending Successful